/

DNTH

Dianthus Therapeutics, Inc.Pre-market

81.57−0.80 −0.97%USD

NasdaqCM · as of Oct 12, 16:00 ET · 15m delay

Open

81.77

Prev close

82.37

Day range

80.9183.77

52-week range

32.22117.88

Volume

853.94K1.06×

Mkt cap

4.56B

P/E ttm

—

Fwd P/E

-17.69

EPS ttm

-4.24

Div yield

0.00%

Earnings

Aug 4, 2026

From 52w high

−30.80%

Price Chart

Yahoo Finance · delayed

DNTHOct 12, 2026O 81.77H 83.77L 80.91C 81.57−0.80 (−0.97%)Vol 853.90K

SMA 50102.12
SMA 20082.40

1Y change +136.71% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

DNTH Dianthus Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.35%
1 month: −23.19%
3 months: −17.31%
6 months: −9.37%
Year to date: +97.94%
1 year: +136.71%

Valuation & ownership

Market cap: 4.56B
Enterprise value: 3.68B
P/E (ttm): —
Forward P/E: -17.69
PEG ratio: —
Price / book: 3.81
Price / sales (ttm): 2396.31
EV / EBITDA: -16.89
EPS (ttm): -4.24
EPS (forward): -4.61
Beta (5y monthly): 0.18
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 55.93M
Float: 55.81M
Short % of float: 18.75%
Short ratio (days): 10.65
Held by insiders: 0.12%
Held by institutions: 127.88%
Avg volume (3m): 802.72K
50-day average: 102.12
200-day average: 82.40
52-week change: +136.71%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 22.1
vs 50-day SMA: −20.12%
vs 200-day SMA: −1.01%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.21%
Realised vol (20d, ann.): 28.4%
From 52-week high: −30.80%
From 52-week low: +153.17%

ANR

Analyst Consensus

15 analysts

Consensus

Strong buy

1.06 on a 1 (strong buy) – 5 (sell) scale

Mean target

140.80

+72.61% implied

Low 122.00Median 134.00High 200.00

Recommendation trend

Now17 / 0 / 0
1m ago17 / 0 / 0

DES

About Dianthus Therapeutics, Inc.

Yahoo Finance profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Sector: Healthcare
Industry: Biotechnology
Employees: 92
Headquarters: New York, NY, United States
Website: dianthustx.com
Officers: Mr. Marino Garcia M.B.A. President, CEO & Director
Mr. Ryan Savitz Executive VP, CFO, Chief Business Officer & Treasurer
Dr. Simrat Randhawa M.B.A., M.D. Executive VP and Head of R&D
Mr. Edward G. Carr Senior VP & Chief Accounting Officer

SEAS

Seasonality · DNTH

2018–2026 · monthly returns

Strongest month Feb +25.18%Weakest month Dec −15.81%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	29.6	3.4	52.1	4.6	5.9	4.8	9.7	-1.2	-16.6	-7.4			+97.9%
2025	1.6	-2.5	-16.0	20.5	-20.4	7.1	11.0	14.0	66.9	-11.1	25.7	-6.3	+89.0%
2024	82.7	30.3	21.2	-28.8	1.2	19.8	15.1	-3.2	-5.0	1.8	-13.9	-9.1	+109.6%
2023	37.5	47.3	-2.5	-1.3	-16.7	16.9	5.3	-6.3	13.9	-12.2	-6.8	-7.0	+62.5%
2022	-26.2	-3.7	-7.9	-50.7	-18.9	3.4	33.3	10.0	-19.9	-8.5	-10.9	-65.2	−91.0%
2021	12.8	18.9	12.7	-1.6	6.0	-20.8	-27.2	-10.1	13.8	-12.1	-12.0	-21.3	−43.5%
2020	-21.6	-1.0	-46.6	29.8	8.5	-15.0	-6.5	3.6	-6.5	-7.2	13.3	9.7	−48.3%
2019	23.0	87.0	25.6	-12.5	1.7	0.6	-8.4	-23.5	-0.7	1.5	27.2	14.5	+166.0%
2018							1.9	6.2	-17.7	-27.0	11.5	-41.7	−57.8%

INSD

Insider Activity · DNTH

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

325.8K shares

Sells, 6 months

310.8K shares

Net shares

+15K

Net change in insider shares

+27.60%

Date	Insider	Transaction	Shares	Value
Aug 31, 2026	Randhawa SimratOfficer	Sale at price 105.19 - 106.74 per share.	23.1K	$2.46M
Aug 31, 2026	Randhawa SimratOfficer	Conversion of Exercise of derivative security at price 17.88 - 22.07 per share.	23.1K	$477.05K
Aug 18, 2026	Read Simon J.Director	Sale at price 117.55 per share.	2.8K	$326.55K
Aug 18, 2026	Read Simon J.Director	Conversion of Exercise of derivative security at price 18.36 per share.	2.8K	$51.00K
Aug 12, 2026	Veness Adam MGeneral Counsel	Conversion of Exercise of derivative security at price 18.17 per share.	15K	$272.55K
Aug 9, 2026	Read Simon J.Director	Sale at price 107.11 - 111.77 per share.	2.8K	$304.23K
Aug 9, 2026	Read Simon J.Director	Conversion of Exercise of derivative security at price 18.36 per share.	2.8K	$50.99K
Aug 9, 2026	Veness Adam MGeneral Counsel	Sale at price 110.38 - 111.18 per share.	20K	$2.21M
Aug 9, 2026	Veness Adam MGeneral Counsel	Conversion of Exercise of derivative security at price 17.88 per share.	20K	$357.60K
Aug 9, 2026	Mcgeorge AnneDirector	Sale at price 107.58 - 111.41 per share.	7.8K	$844.82K
Aug 9, 2026	Mcgeorge AnneDirector	Conversion of Exercise of derivative security at price 11.20 - 19.36 per share.	7.8K	$97.00K
Aug 6, 2026	Garcia MarinoChief Executive Officer	Sale at price 107.49 - 110.76 per share.	166K	$17.95M
Aug 6, 2026	Garcia MarinoChief Executive Officer	Conversion of Exercise of derivative security at price 8.44 per share.	166K	$1.40M
Jul 8, 2026	Savitz RyanChief Financial Officer	Sale at price 100.22 - 101.97 per share.	31.2K	$3.16M
Jul 8, 2026	Savitz RyanChief Financial Officer	Conversion of Exercise of derivative security at price 21.77 per share.	31.2K	$680.29K
Jun 16, 2026	Veness Adam MGeneral Counsel	Sale at price 80.34 - 81.38 per share.	30K	$2.42M
Jun 16, 2026	Veness Adam MGeneral Counsel	Conversion of Exercise of derivative security at price 17.88 per share.	30K	$536.40K
May 31, 2026	Randhawa SimratOfficer	Sale at price 89.72 - 91.37 per share.	26.5K	$2.40M
May 31, 2026	Randhawa SimratOfficer	Conversion of Exercise of derivative security at price 8.44 - 22.07 per share.	26.5K	$500.20K
May 7, 2026	Soteropoulos PaulaDirector	Sale at price 85.47 per share.	599	$51.20K

DNTH

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

DNTH

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Dianthus Therapeutics, Inc.

Seasonality · DNTH

Insider Activity · DNTH

Congress Trades · DNTH

Investors Holding DNTH

Investors Holding DNTH

Congress Trades · DNTH

Insider Activity · DNTH

Seasonality · DNTH

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Dianthus Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News